ArticleBJU international2026
Diagnostic and prognostic utility of PSMA-PET/CT in node-metastatic prostate cancer.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- A seven-variable clinical prediction model for bone metastasis at initial diagnosis of prostate cancer.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveTo measure the sensitivity of prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) for detecting lymph node involvement (LNI) in patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (PLND) and to evaluate whether PSMA nodal status independently predicts oncological outcomes. PATIENTS AND
methodsWe identified patients with localised or locoregional prostate cancer who underwent PSMA-PET/CT followed by RP (2021-2024) at a high-volume centre and had pathologically confirmed LNI (pN1) on PLND. We evaluated the sensitivity of PSMA-PET/CT for detecting pN1 disease. Associations between PSMA-PET/CT and biochemical recurrence (BCR), any radiographic recurrence, and distant recurrence were evaluated using Cox regression models.
resultsOverall, PSMA-PET/CT detected LNI in 24 of 79 patients with pN1 disease, a sensitivity of 30% (95% confidence interval [CI] 21-42%). PSMA-positive nodal disease (clinical N1 [cN1]) was significantly associated with BCR (hazard ratio [HR] 2.34, 95% CI 1.26-4.36; P = 0.009), radiographic recurrence (HR 4.23, 95% CI 1.86-9.58; P < 0.001), and distant radiographic recurrence (HR 5.81, 95% CI 1.79-18.8; P = 0.002). The 1-year risk of BCR approached 90% for those with cN1 disease. Median metastatic focus size was larger in cN1 vs cN0 patients (1.1 vs 0.3 cm; P < 0.001). Limitations include relatively short follow-up.
conclusionsDue to low sensitivity, PSMA-PET/CT without evidence of nodal disease does not obviate the need for PLND. However, PSMA-avid nodal disease portends a nearly inevitable short interval recurrence and radiographic progression, supporting treatment intensification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.